Hybridoma cell strain secreting ethoxyquin monoclonal antibody and application of hybridoma cell strain
By synthesizing ethoxyquinoline antigen and adjuvant for immunoinjection, hybridoma cell lines secreting ethoxyquinoline monoclonal antibodies were screened, which solved the problem of insufficient sensitivity of existing detection methods and achieved ethoxyquinoline. High sensitivity detection provides a fast and simple detection solution.
Patent Information
- Application Number
- CN202411021556.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-08
AI Technical Summary
The existing ethoxyquinoline detection methods have insufficient sensitivity and specificity, and require thorough sample purification and high solvent consumption, resulting in high detection costs and lack of fast and easy detection methods.
By synthesizing ethoxyquinoline hapten and complete antigen, immunoinjection was performed using Freund's adjuvant, mouse spleen cells and myeloma cells were fused, and hybridoma cell lines secreting ethoxyquinoline monoclonal antibodies were screened, and Through indirect competition enzyme-linked immunosylation, ethoxyquinoline monoclonal antibodies with high specificity and high sensitivity were finally prepared.
The obtained ethoxyquinoline monoclonal antibody has high detection sensitivity, with an IC50 value of 7.14ng/mL. It can be used to prepare chips, test strips and kits to achieve high sensitivity and specificity of ethoxyquinoline. Sexual immunoassay.
Smart Images

Figure CN118909959A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunochemistry, in particular to a hybridoma cell strain secreting ethoxyquinoline monoclonal antibody and application thereof. Background Art
[0002] The common name of ethoxyquin in English is: Ethoxyquin, and its chemical name is: 6-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline; ethoxyquinoline has the effects of preservation and anti-oxidation. It is mainly used for the preservation of fruits, and the prevention and treatment of apple skin disease, black skin disease of pears and bananas. It can also be used for the anti-oxidation of vitamin A, vitamin D, β-carotene, fat and other substances. The effect is basically the same as BHA and BHT, but the price is cheaper. At the same time, ethoxyquinoline can also be sprayed on the surface of feed by spraying, which can effectively prevent the rancidity and oxidation of fat in feed, and prevent the deterioration of vitamins, and has an antioxidant effect. If used excessively (the addition amount exceeds 0.1%), it will cause the color of pork fat to darken or turn yellow, affecting the quality of the carcass.
[0003] At present, the detection method of ethoxyquinoline is mainly instrumental detection, and the commonly used methods are gas chromatography, liquid chromatography and gas chromatography-mass spectrometry. Although these chromatography-based methods have high sensitivity and specificity, they have some disadvantages, such as the need for thorough sample cleanup, high solvent consumption, expensive equipment and skilled technicians. Therefore, a rapid and simple method for detecting ethoxyquinoline residues is needed.
[0004] Enzyme-linked immunosorbent assay (ELISA) is an extremely efficient, sensitive and rapid detection method. It has simple sample pretreatment, few purification steps, large analysis capacity, low detection cost and easy operation. It is suitable for rapid on-site detection of a large number of samples, so it has been widely used in drug residue analysis. The premise of using enzyme-linked immunosorbent assay to detect ethoxyquinoline is to obtain a monoclonal antibody with high specificity and high sensitivity to ethoxyquinoline. Therefore, it is critical to find a method for preparing a monoclonal antibody with high specificity and high sensitivity to ethoxyquinoline. Chinese patent CN104569398A discloses an enzyme-linked immunosorbent assay kit for detecting ethoxyquinoline and its application. Ethoxyquinoline hapten is prepared by reacting ethoxyquinoline with phthalic anhydride, thereby further preparing ethoxyquinoline monoclonal antibody. However, the IC of the enzyme-linked immunosorbent assay kit is 50 The value range is only 1.8-2.5μg / L. Therefore, how to prepare ethoxyquinoline hapten and complete antigen and how to make mice produce strong immune effects, how to make the prepared hybridoma cell lines successfully secrete ethoxyquinoline monoclonal antibodies, and how to make the secreted ethoxyquinoline monoclonal antibodies have strong specificity and high sensitivity require further research and exploration. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a hybridoma cell strain secreting ethoxyquinoline monoclonal antibody and its application. The ethoxyquinoline complete antigen is prepared by synthesizing ethoxyquinoline hapten, and the ethoxyquinoline complete antigen is mixed with an equal amount of Freund's adjuvant for emulsification, and BALB / c mice are immunized by multiple subcutaneous injections on the back of the neck. The first immunization is emulsified with complete Freund's adjuvant, multiple booster immunizations are performed with incomplete Freund's adjuvant, and the last sprint immunization is performed with ethoxyquinoline complete antigen. The spleen cells of high-titer and high-sensitivity mice are fused with mouse myeloma cells, and a selection medium is used to screen the hybrid cells after the fusion of the two cells; the cells are then screened by indirect competitive enzyme-linked immunosorbent assay, and multiple subclonings are performed to finally obtain a hybridoma cell strain secreting ethoxyquinoline monoclonal antibody.
[0006] The first object of the present invention is to provide a hybridoma cell strain secreting ethoxyquinoline monoclonal antibody, wherein the deposit number of the hybridoma cell strain is CGMCC NO.45907.
[0007] Furthermore, the method for preparing the hybridoma cell line comprises the following steps:
[0008] Step S1, preparing ethoxyquinoline hapten, using the obtained ethoxyquinoline hapten to prepare ethoxyquinoline complete antigen, mixing the obtained ethoxyquinoline complete antigen with complete Freund's adjuvant to obtain antigen-containing complete Freund's adjuvant, and emulsifying the obtained ethoxyquinoline complete antigen with incomplete Freund's adjuvant to obtain antigen-containing incomplete Freund's adjuvant;
[0009] Step S2, using the antigen-containing complete Freund's adjuvant obtained in step S1 to perform the first immunization on the immunized animal;
[0010] Step S3, performing booster immunization on the immunized animal after immunization in step S2 using the incomplete Freund's adjuvant containing the antigen obtained in step S1, and performing sprint immunization using the ethoxyquinoline complete antigen;
[0011] Step S4, taking the spleen cells of the immunized animal subjected to sprint immunization in step S3 and performing cell fusion with myeloma cells to obtain the hybridoma cell line;
[0012] Wherein, the molecular structural formula of the ethoxyquinoline hapten is: The molecular structural formula of the ethoxyquinoline complete antigen is:
[0013] The second object of the present invention is to provide the use of the hybridoma cell line in the preparation of ethoxyquinoline monoclonal antibodies.
[0014] The third object of the present invention is to provide an ethoxyquinoline monoclonal antibody, wherein the ethoxyquinoline monoclonal antibody is secreted by the above hybridoma cell line.
[0015] The fourth object of the present invention is to provide a composition comprising the above hybridoma cell line and / or the above ethoxyquinoline monoclonal antibody.
[0016] A fifth object of the present invention is to provide a chip, wherein the chip contains the hybridoma cell line, the ethoxyquinoline monoclonal antibody or the composition.
[0017] The sixth object of the present invention is to provide a test strip, wherein the test strip contains the hybridoma cell line, the ethoxyquinoline monoclonal antibody or the composition.
[0018] Furthermore, the test strip also includes a sample pad, a colloidal gold pad, a water-absorbing pad and an acetate fiber pad, and the colloidal gold pad is coated with colloidal gold-labeled ethoxyquinoline monoclonal antibody.
[0019] A seventh object of the present invention is to provide a kit, which contains the above hybridoma cell line, the above ethoxyquinoline monoclonal antibody or the above composition.
[0020] Furthermore, the kit also includes an ELISA plate, an ethoxyquinoline-coated antigen, an ethoxyquinoline standard solution, an enzyme-labeled secondary antibody and a color developing solution.
[0021] The eighth object of the present invention is to provide the use of the above-mentioned ethoxyquinoline monoclonal antibody, the above-mentioned composition, the above-mentioned chip, the above-mentioned test strip or the above-mentioned kit in detecting ethoxyquinoline.
[0022] Beneficial effects of the present invention:
[0023] The hybridoma cell line secreting ethoxyquinoline monoclonal antibody provided by the present invention has good detection sensitivity to ethoxyquinoline, IC 50 The value is 7.14ng / mL, which provides the core biological raw materials for the establishment of a high-sensitivity and high-specific immunoassay method for ethoxyquin, and can be used to prepare ethoxyquin detection products in different forms such as chips, test strips and kits.
[0024] Biomaterial Deposit
[0025] The hybridoma cell line secreting ethoxyquinoline monoclonal antibody is deposited in the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Administration, located at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named as monoclonal cell line, the deposit date is April 18, 2024, and the deposit number is CGMCC No.45907. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein
[0027] Figure 1 This is the standard curve of inhibition of ethoxyquinoline by the ethoxyquinoline monoclonal antibody in the embodiment of the present invention. DETAILED DESCRIPTION
[0028] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0029] The culture medium involved in the embodiment is as follows:
[0030] RPMI-1640 medium (mg / L): L-arginine 290, L-asparagine 50, L-aspartic acid 20, L-cystine dihydrochloride 65.15, L-glutamic acid 20, glycine 10, L-histidine 15, L-hydroxyproline 20, L-isoleucine 50, L-leucine 50, L-lysine hydrochloride 40, L-methionine 15, L-phenylalanine 15, L-proline 20, L-serine 30, L-threonine 20, L-tryptophan 5, L-tyrosine 23.19, L-valine 20, p-aminobenzoic acid 1, calcium nitrate 100, anhydrous magnesium sulfate 48.84, anhydrous sodium dihydrogen phosphate 676.13, potassium chloride 400, sodium chloride 6000, glucose 2000, reduced glutathione 1, phenol red 5, L-glutamine 300, biotin 0.2, D-calcium pantothenate 0.25, folic acid 1, i-inositol 35, niacinamide 1, choline chloride 3, pyridoxine hydrochloride 1, riboflavin 0.2, thiamine hydrochloride 1, vitamin B12 0.005, sodium bicarbonate 2000.
[0031] The reagents involved in the embodiment are as follows:
[0032] Carbonate buffer (CBS): Weigh 1.59 g of Na2CO3 and 2.93 g of NaHCO3, dissolve them in a small amount of double distilled water respectively and mix them, add double distilled water to about 800 mL and mix well, adjust the pH to 9.6, add double distilled water to 1000 mL, and store at 4°C for later use.
[0033] Phosphate buffered saline (PBS): 8.00 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, 2.9 g Na2HPO4·12H2O, dissolved in 800 mL pure water, adjusted to pH 7.2-7.4 with NaOH or HCl, and made up to 1000 mL;
[0034] PBST: PBS containing 0.05% Tween 20;
[0035] Antibody diluent: PBS containing 0.1% gelatin;
[0036] TMB colorimetric solution: Solution A: 18.43g Na2HPO4·12H2O, 9.33g citric acid, dilute to 1000mL with pure water; Solution B: 60mg TMB dissolved in 100mL ethylene glycol. Mix solution A and solution B in a ratio of 5:1 to obtain the TMB colorimetric solution, and mix again when using.
[0037] The detection method involved in the embodiment is as follows:
[0038] Ethoxyquin inhibition rate detection method: The most suitable antigen and antibody concentrations in ic-ELISA were selected by chessboard test. The antigen was diluted to 0.01, 0.03, 0.1 and 0.3 μg / mL with carbonate buffer (CBS), and the antibody was diluted to 0.03, 0.1, 0.3 and 1 μg / mL with antibody diluent. After selecting the optimal working point, the ethoxyquin standard was diluted to 8 concentrations (0, 0.222, 0.666, 2, 6, 18, 54 and 162 ng / mL), and the ic-ELISA operation steps were followed. Finally, OriginPro8.5 was used to draw the graph to obtain the ethoxyquin standard inhibition curve and calculate the IC 50 .
[0039] Example 1: Synthesis of ethoxyquinoline hapten
[0040] Since the ethoxyquinoline small molecule is not immunogenic and cannot stimulate mice to produce an immune response and then produce antibodies, ethoxyquinoline needs to be coupled to the protein through protein coupling technology to make it immunogenic; the active groups commonly used in protein coupling technology include amino, carboxyl, hydroxyl and thiol groups. Since the ethoxyquinoline molecular structure does not contain these active groups, ethoxyquinoline is derivatized.
[0041] The ethoxyquinoline analog (CAS: 72107-05-2) was dissolved in a dry DMF solution, and 1.2 eq of tert-butyl 4-bromobutyrate (CAS: 110661-91-1) was added, followed by the addition of 1.5 eq of sodium hydride under ice bath conditions, and the mixture was stirred at room temperature overnight under argon conditions. After the reaction was completed, methanol was added to quench the reaction, and the solvent was removed by concentration under reduced pressure. The product was separated and purified by column chromatography and dissolved in a DCM solution. An equal volume of DCM / TFA solution was added under ice bath conditions, and the mixture was stirred for 2 h under ice bath conditions. Excess TFA was removed by toluene, and the reaction was repeated three times. Finally, the ethoxyquinoline hapten was separated and purified by column chromatography.
[0042] The structural formula of the obtained ethoxyquinoline hapten is:
[0043] Example 2: Synthesis of ethoxyquinoline complete antigen
[0044] Weigh 6 mg of ethoxyquinoline hapten and 4.4 mg of N-hydroxysuccinimide (NHS), dissolve in 200 μL of N,N-dimethylformamide (DMF), and stir at room temperature for 10 minutes; then weigh 7.5 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), add to the ethoxyquinoline hapten solution, stir at room temperature for 6-8 hours to activate. Take 6 mg of keyhole limpet hemocyanin (KLH), add to 3 mL of 0.01 M carbonate buffer (CBS), fully dissolve, slowly add the activated hapten to the diluent in which KLH is dissolved, and stir at room temperature overnight. Then dialyze with 0.01 M PBS solution to remove unreacted small molecules, obtain a relatively pure complete antigen, and identify it by ultraviolet absorption scanning method.
[0045] The structural formula of the obtained ethoxyquinoline complete antigen is:
[0046]
[0047] Example 3: Synthesis of ethoxyquinoline coating
[0048] 3.2 mg of ethoxyquinoline hapten and 2.4 mg of N-hydroxysuccinimide (NHS) were dissolved in 200 μL of anhydrous N,N-dimethylformamide (DMF) and stirred at room temperature for 10 min; 4.2 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was dissolved in the above solution and stirred at room temperature for 6-8 h to obtain a hapten activation solution; 6 mg of chicken ovalbumin (OVA) was dissolved in carbonate buffer (CBS); the hapten activation solution was slowly added to the protein diluent and stirred at room temperature overnight. Then, the reaction solution was dialyzed with 0.01 M PBS solution to remove unreacted small molecules to obtain the coating source.
[0049] Example 4: Preparation of hybridoma cell lines secreting ethoxyquinoline monoclonal antibodies
[0050] 1. Acquisition of animal immunity
[0051] After the complete ethoxyquinoline antigen was mixed and emulsified with an equal amount of Freund's adjuvant, BALB / c mice were immunized by multiple subcutaneous injections at the back of the neck (except for sprint immunization); the first immunization used complete Freund's adjuvant, with a dose of 100 μg / mouse; multiple booster immunizations used incomplete Freund's adjuvant and the dose was halved to 50 μg / mouse; no adjuvant was used for sprint immunization, and it was directly diluted with physiological saline and injected intraperitoneally, and the dose was halved again to 25 μg / mouse; the first immunization and the second booster immunization were separated by one month, the multiple booster immunizations were separated by 21 days, and the sprint immunization and the last booster immunization were separated by 18-21 days; the immune effect of mice was observed by indirect competitive enzyme-linked immunosorbent assay (ic-ELISA), that is, the titer and inhibition of mouse serum were detected;
[0052] 2. Cell fusion
[0053] Three days after the sprint immunization, cell fusion was performed according to the conventional PEG (polyethylene glycol, molecular weight 4000) method. The specific steps are as follows:
[0054] a. Cut off the tail to collect blood. After killing the mice by cervical dislocation, immediately put them in 75% alcohol for disinfection and soak for about 5 minutes. Take out the spleen of the mice aseptically, grind them moderately with the rubber tip of the syringe and pass them through a 200-mesh cell sieve to obtain a spleen cell suspension, collect them, centrifuge them (1200rpm, 8min), wash the spleen cells three times with RPMI-1640 medium, dilute the spleen cells to a certain volume after the last centrifugation, count them, and set aside;
[0055] b. Collect SP2 / 0 cells: 7-10 days before fusion, SP2 / 0 tumor cells were amplified in RPMI-1640 medium containing 10% FBS (fetal bovine serum) in a 5% CO2 incubator. Before fusion, the number of SP2 / 0 tumor cells was required to reach 1-4×10 7 , ensure that SP2 / 0 tumor cells are in the logarithmic growth phase before fusion. When fusion occurs, tumor cells are collected, suspended in RPMI-1640 basal culture medium, and cell counts are performed;
[0056] c. Fusion process 7min: In the first minute, 1mL of PEG 4000 was added to the cells from slow to fast; in the second minute, it was allowed to stand; in the third and fourth minutes, 1mL of RPMI-1640 medium was added within 1min; in the fifth and sixth minutes, 2mL of RPMI-1640 medium was added within 1min; in the seventh minute, 1mL of RPMI-1640 medium was added every 10s. Except for the second minute, the solution was shaken continuously at other times. Then, it was warmed at 37℃ for 5min; centrifuged (800rpm, 8min), the supernatant was discarded, and the cell was resuspended in RPMI-1640 screening culture medium containing 20% fetal bovine serum and 2% 50×HAT, and added to a 96-well cell plate at 200μL / well, and cultured in a 37℃, 5% CO2 incubator.
[0057] 3. Cell screening and cell line establishment
[0058] On the third day after cell fusion, the fused cells were half-changed with RPMI-1640 screening medium, and on the fifth day, the medium was fully replaced with RPMI-1640 transition medium containing 20% fetal bovine serum and 1% 100×HT. On the seventh day, the cell supernatant was taken for screening.
[0059] The screening is divided into two steps: the first step is to screen out the positive cell wells by the ic-ELISA method, and the second step is to use ethoxyquinoline as a standard and use the ic-ELISA method to measure the inhibitory effect on the positive cells.
[0060] The cell wells with better inhibition of ethoxyquinoline standard were selected, subcloned by limiting dilution method, and tested by the same method seven days later.
[0061] Subcloning was performed at least three times according to the above method to finally obtain the ethoxyquinoline monoclonal antibody cell line.
[0062] Example 5: Preparation and identification of ethoxyquinoline monoclonal antibodies
[0063] 8-10 week old BALB / c mice were taken and each mouse was intraperitoneally injected with 1 mL of sterile paraffin oil. Seven days later, each mouse was intraperitoneally injected with 1×10 6 Ethoxyquinoline hybridoma cells, ascites was collected from the seventh day, and the ascites was used to purify antibodies by the caprylic acid-saturated ammonium sulfate method.
[0064] Under slightly acidic conditions, octanoic acid can precipitate other impurities in the ascites except IgG immunoglobulin, and then centrifuge and discard the precipitate; then use an equal amount of saturated ammonium sulfate solution to precipitate IgG type monoclonal antibodies, centrifuge, discard the supernatant, dissolve with 0.01M PBS solution (pH 7.4), dialyze and desalt, and finally obtain the purified monoclonal antibody and store it at -20°C.
[0065] IC of ethoxyquinoline monoclonal antibody was measured using indirect competitive ELISA 50 The value was 7.14 ng / mL, indicating good sensitivity to ethoxyquin and can be used for ethoxyquin immunoassay detection.
[0066] Example 6: Application of ethoxyquinoline monoclonal antibody
[0067] The monoclonal antibody prepared by hybridoma cell line through ascites in vivo was applied to ethoxyquinoline addition recovery test. The specific steps are as follows:
[0068] (1) Coat a 96-well ELISA plate with 0.1 μg / mL of the coating agent diluted with carbonate buffer (CBS), 100 μL per well, bake at 37°C for 2 h, wash the plate three times with PBST, 200 μL per well each time, 3 min each time, and pat dry;
[0069] (2) Block with CBS containing 0.2% gelatin, 200 μL per well, bake at 37°C for 2 h, wash the plate three times with PBST, 200 μL per well each time, 3 min each time, and pat dry;
[0070] (3) Prepare ethoxyquinoline standard solutions of 0 ng / mL, 0.222 ng / mL, 0.666 ng / mL, 2 ng / mL, 6 ng / mL, 18 ng / mL, 54 ng / mL and 162 ng / mL respectively with phosphate buffered saline (PBS), add the standard solutions and the sample extracts to be tested to the blocked ELISA plate, 50 μL per well, repeat 3 wells for each sample, then add 50 μL of ethoxyquinoline monoclonal antibody diluted to 0.1 μg / mL to each well, react at 37°C for 30 min, wash the plate and pat dry;
[0071] (4) Add 100 μL of HRP-labeled goat anti-mouse IgG secondary antibody diluted 1:3000 in PBS containing 0.1% gelatin to each well, react at 37°C for 30 min, wash the plate and pat dry;
[0072] (5) Add 100 μL of TMB colorimetric solution to each well. After color development at 37°C for 15 min, add 50 μL of 2 mol / L H2SO4 stop solution to each well and measure the absorbance at 450 nm.
[0073] (6) Addition recovery and sample pretreatment:
[0074] Apple was selected as the test sample.
[0075] Wash and chop the sample to be tested, and blend it in a blender. Weigh three samples, 5 g each, and add 50 ppb, 100 ppb, and 200 ppb of ethoxyquinoline standard to the samples (according to the linear range of the antibody and IC 50 Set the added concentration), vortex and shake for 2 minutes. Add 10mL methanol, 1g NaCl, 5g anhydrous Na2SO4, vortex and shake for 5 minutes, centrifuge at 4000rpm for 10 minutes, collect the supernatant, take 1mL of the supernatant, blow dry with nitrogen, and reconstitute with 5mL PBS.
[0076] The recovery rates of the spike-in recovery test were 92%, 104% and 108% respectively by indirect competitive ELISA.
[0077] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A hybridoma cell line secreting ethoxyquinoline monoclonal antibody, characterized in that: The deposit number of the hybridoma cell line is CGMCC NO.45907.
2. Use of the hybridoma cell line according to claim 1 in the preparation of ethoxyquinoline monoclonal antibodies.
3. An ethoxyquinoline monoclonal antibody, characterized in that: The ethoxyquinoline monoclonal antibody is secreted by the hybridoma cell line according to claim 1.
4. A composition, characterized in that: The composition comprises the hybridoma cell line according to claim 1 and / or the ethoxyquinoline monoclonal antibody according to claim 3.
5. A chip, characterized in that: The chip contains the hybridoma cell line according to claim 1, the ethoxyquinoline monoclonal antibody according to claim 3 or the composition according to claim 4.
6. A test strip, characterized in that: The test strip contains the hybridoma cell line according to claim 1, the ethoxyquinoline monoclonal antibody according to claim 3 or the composition according to claim 4.
7. The test strip according to claim 6, characterized in that: The test strip also includes a sample pad, a colloidal gold pad, a water-absorbing pad and an acetate fiber pad, and the colloidal gold pad is coated with ethoxyquinoline monoclonal antibodies marked with colloidal gold.
8. A kit, characterized in that: The kit contains the hybridoma cell line according to claim 1, the ethoxyquinoline monoclonal antibody according to claim 3 or the composition according to claim 4.
9. The kit according to claim 8, characterized in that: The kit also includes an ELISA plate, an ethoxyquinoline-coated antigen, an ethoxyquinoline standard solution, an enzyme-labeled secondary antibody and a color developing solution.
10. Use of the ethoxyquinoline monoclonal antibody according to claim 3, the composition according to claim 4, the chip according to claim 5, the test strip according to any one of claims 6-7 or the kit according to any one of claims 8-9 in detecting ethoxyquinoline.
Citation Information
Patent Citations
Enzyme-linked immunoassay kit for detecting ethoxyquinoline and application thereof
CN104569398A
